Exodus Point Capital Management, LP Alaunos Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.62 - $1.17 $18,846 - $35,564	-30,397 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$1.09 - $1.89 $33,132 - $57,450	30,397 New	30,397 $33,000
Q3 2021 Nov 15, 2021	SELL	$1.44 - $2.73 $99,188 - $188,045	-68,881 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $181,157 - $252,793	68,881 New	68,881 $182,000
Q1 2021 May 17, 2021	SELL	$2.82 - $5.6 $58,884 - $116,933	-20,881 Closed	0 $0

Q4 2020 Feb 16, 2021	BUY	$2.09 - $3.09 $21,430 - $31,684	10,254 Added 96.49%	20,881 $53,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $3.43 $25,398 - $36,450	10,627 New	10,627 $27,000
Q3 2019 Nov 14, 2019	SELL	$4.13 - $6.94 $80,948 - $136,024	-19,600 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$3.98 - $6.2 $78,008 - $121,520	19,600 New	19,600 $114,000

106K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $141M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.